Trials / Completed
CompletedNCT00699608
An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.
A Randomised, Double-blind, Double-dummy, Placebo-controlled, 3-way Crossover Study to Evaluate Potential Next-day Residual Effects of a Single Evening Dose of 3mg Eszopiclone and 7.5mg Zopiclone in Healthy Adult Subjects.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 25 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
This study will explore potential next-day residual effects of a single evening dose of 3mg of the hypnotic, eszopiclone, 7.5mg of zopiclone, and placebo, in healthy adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK1755165; placebo; zopiclone | Subjects receive either 3mg GSK1755165, matching placebo or 7.5mg zopiclone |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2008-06-18
- Last updated
- 2012-06-05
- Results posted
- 2010-05-12
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00699608. Inclusion in this directory is not an endorsement.